Skip to main content
. 2021 Dec 9;15:775144. doi: 10.3389/fnhum.2021.775144

TABLE 4.

Univariate analysis of the correlation between cognition and benzodiazepines.

BZDs use (n = 30) Non-BZDs use (n = 90) P-value
MMSE scores 26.00 (23.00, 28.00) 28.00 (26.00, 28.25) 0.013
MoCA scores 21.20 ± 3.49 23.50 ± 3.65 0.003
Long-term delayed recall of AVLT scores 5.00 (4.00, 6.00) 7.00 (3.75, 9.75) 0.184
TMT-B scores 126.00 (81.00, 300.00) 85.00 (57.75, 217.00) 0.062
BNT-30 scores 25.80 ± 3.02 25.42 ± 3.30 0.581
CDT scores 4.00 (3.00, 4.00) 4.00 (3.00, 4.00) 0.596
DST scores 4.00 (3.00, 5.00) 5.00 (4.00, 5.25) 0.004
HAMD scores 10.00 (6.00, 13.00) 9.00 (6.75, 11.50) 0.766
HAMA scores 10.00 (6.00, 12.00) 9.00 (7.00, 15.25) 0.808
Male 12 (20.83%) 27 (20.83%) 0.311
Age (years) 64.20 ± 6.98 59.22 ± 5.52 0.000
Married/cohabitating 24 (80.00%) 85 (94.44%) 0.045
Living with others 24 (80.00%) 87 (96.67%) 0.009
Low income 18 (60.00%) 46 (51.11%) 0.398
Education (years) 11.27 ± 3.63 11.75 ± 3.37 0.505
BMI, kg/m2 22.95 ± 2.55 23.63 ± 2.86 0.247
Smoking, % 4 (13.33%) 19 (21.11%) 0.349
Concomitant illness
 Hypertension, % 16 (53.33%) 22 (24.44%) 0.003
 Diabetes mellitus, % 6 (20.00%) 11 (12.22%) 0.450
 Coronary heart disease, % 4 (13.33%) 8 (8.89%) 0.725
 Dyslipidemia, % 8 (26.67%) 39 (43.33%) 0.105
 Gout, % 2 (6.67%) 2 (2.22%) 0.557
Insomnia
 Age at onset (years) 50.00 (28.00, 58.00) 48.00 (42.25, 54.25) 0.872
 Insomnia duration (years) 17.00 (5.00, 34.00) 10.00 (3.00, 15.25) 0.214
 PSQI scores 14.27 ± 3.05 13.90 ± 2.71 0.535